Literature DB >> 33489907

Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?

Ugo Giovanni Falagario1, Giovanni Silecchia2, Salvatore Mariano Bruno1, Michele Di Nauta1, Mario Auciello1,2, Francesca Sanguedolce3, Paola Milillo4, Luca Macarini4, Oscar Selvaggio1, Giuseppe Carrieri1, Luigi Cormio1,2.   

Abstract

BACKGROUND: European Association of Urology (EAU) guidelines recommend using risk-calculators (RCs), imaging or additional biomarkers in asymptomatic men at risk of prostate cancer (PCa).
OBJECTIVES: To compare the performance of mpMRI, a RC we recently developed and two commonly used RC not including mpMRI in predicting the risk of PCa, as well as the added value of mpMRI to each RC. DESIGN SETTING AND PARTICIPANTS: Single-center retrospective study evaluating 221 biopsy-naïve patients who underwent prebiopsy mpMRI. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients' probabilities of any PCa and clinically significant PCa (csPC, defined as Gleason-Score ≥3 + 4) were computed according to mpMRI, European Randomized Study of Screening for Prostate Cancer RC (ERSPC-RC), the Prostate Biopsy Collaborative Group RC (PBCG-RC) and the Foggia Prostate Cancer RC (FPC-RC). Logistic regression, AUC, and Decision curve analysis (DCA) were used to assess the accuracy of tested models. RESULTS AND LIMITATION: The FPC-RC outperformed mpMRI in diagnosing both any PCa (AUC 0.76 vs 0.69) and csPCa (AUC 0.80 vs 0.75). Conversely mpMRI showed a higher accuracy in predicting any PCa compared to the PBCG-RC and the ERSPC-RC but similar performances in predicting csPCa. At multivariable analysis predicting csPCa and any PCa, the addition of mpMRI findings improved the accuracy of each calculator. DCA showed that the FPC-RC provided a greater net benefit than mpMRI and the other RCs. The addition of mpMRI findings improved the net benefit provided by each calculator.
CONCLUSIONS: mpMRI was outperformed by the novel FPC-RC and showed similar performances compared to the PBCG and ERSPC RCs in predicting csPCa. The addition of mpMRI findings improved the diagnostic accuracy of each of these calculators.
Copyright © 2021 Falagario, Silecchia, Bruno, Di Nauta, Auciello, Sanguedolce, Milillo, Macarini, Selvaggio, Carrieri and Cormio.

Entities:  

Keywords:  clinically significant prostate cancer; decision curve analysis; mpMRI; prostate cancer; risk calculator

Year:  2021        PMID: 33489907      PMCID: PMC7821426          DOI: 10.3389/fonc.2020.603384

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  31 in total

1.  A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.

Authors:  Ethan Wajswol; Jared S Winoker; Harry Anastos; Ugo Falagario; Kennedy Okhawere; Alberto Martini; Patrick-Julien Treacy; Nicholas Voutsinas; Cynthia J Knauer; John P Sfakianos; Sara C Lewis; Bachir A Taouli; Ardeshir R Rastinehad
Journal:  BJU Int       Date:  2019-12-23       Impact factor: 5.588

2.  Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Authors:  Jan Philipp Radtke; Manuel Wiesenfarth; Claudia Kesch; Martin T Freitag; Celine D Alt; Kamil Celik; Florian Distler; Wilfried Roth; Kathrin Wieczorek; Christian Stock; Stefan Duensing; Matthias C Roethke; Dogu Teber; Heinz-Peter Schlemmer; Markus Hohenfellner; David Bonekamp; Boris A Hadaschik
Journal:  Eur Urol       Date:  2017-04-08       Impact factor: 20.096

3.  Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.

Authors:  Alp Tuna Beksac; Shivaram Cumarasamy; Ugo Falagario; Paige Xu; Mandeep Takhar; Mohamed Alshalalfa; Akriti Gupta; Sonya Prasad; Alberto Martini; Hari Thulasidass; Richa Rai; Mark Berger; Stefanie Hectors; Jennifer Jordan; Elai Davicioni; Sujit Nair; Kenneth Haines; Sara Lewis; Ardeshir Rastinehad; Kamlesh Yadav; Isuru Jayaratna; Bachir Taouli; Ashutosh Tewari
Journal:  J Urol       Date:  2018-07-03       Impact factor: 7.450

4.  Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.

Authors:  Olivier Rouvière; Philippe Puech; Raphaële Renard-Penna; Michel Claudon; Catherine Roy; Florence Mège-Lechevallier; Myriam Decaussin-Petrucci; Marine Dubreuil-Chambardel; Laurent Magaud; Laurent Remontet; Alain Ruffion; Marc Colombel; Sébastien Crouzet; Anne-Marie Schott; Laurent Lemaitre; Muriel Rabilloud; Nicolas Grenier
Journal:  Lancet Oncol       Date:  2018-11-21       Impact factor: 41.316

5.  A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.

Authors:  Pim J van Leeuwen; Andrew Hayen; James E Thompson; Daniel Moses; Ron Shnier; Maret Böhm; Magdaline Abuodha; Anne-Maree Haynes; Francis Ting; Jelle Barentsz; Monique Roobol; Justin Vass; Krishan Rasiah; Warick Delprado; Phillip D Stricker
Journal:  BJU Int       Date:  2017-03-31       Impact factor: 5.588

Review 6.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

7.  Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.

Authors:  Arnout R Alberts; Monique J Roobol; Jan F M Verbeek; Ivo G Schoots; Peter K Chiu; Daniël F Osses; Jasper D Tijsterman; Harrie P Beerlage; Christophe K Mannaerts; Lars Schimmöller; Peter Albers; Christian Arsov
Journal:  Eur Urol       Date:  2018-08-03       Impact factor: 20.096

8.  Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials).

Authors:  Ileana Montoya Perez; Ivan Jambor; Tommi Kauko; Janne Verho; Otto Ettala; Ugo Falagario; Harri Merisaari; Aida Kiviniemi; Pekka Taimen; Kari T Syvänen; Juha Knaapila; Marjo Seppänen; Antti Rannikko; Jarno Riikonen; Markku Kallajoki; Tuomas Mirtti; Tarja Lamminen; Jani Saunavaara; Tapio Pahikkala; Peter J Boström; Hannu J Aronen
Journal:  J Magn Reson Imaging       Date:  2019-11-21       Impact factor: 4.813

9.  External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.

Authors:  Karim Saba; Marian S Wettstein; Laura Lieger; Andreas M Hötker; Olivio F Donati; Holger Moch; Donna P Ankerst; Cédric Poyet; Tullio Sulser; Daniel Eberli; Ashkan Mortezavi
Journal:  J Urol       Date:  2019-10-25       Impact factor: 7.450

10.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079

View more
  4 in total

1.  The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.

Authors:  Sneha Parekh; Parita Ratnani; Ugo Falagario; Dara Lundon; Deepshikha Kewlani; Jordan Nasri; Zach Dovey; Dimitrios Stroumbakis; Daniel Ranti; Ralph Grauer; Stanislaw Sobotka; Adriana Pedraza; Vinayak Wagaskar; Lajja Mistry; Ivan Jambor; Anna Lantz; Otto Ettala; Armando Stabile; Pekka Taimen; Hannu J Aronen; Juha Knaapila; Ileana Montoya Perez; Giorgio Gandaglia; Alberto Martini; Wolfgang Picker; Erik Haug; Luigi Cormio; Tobias Nordström; Alberto Briganti; Peter J Boström; Giuseppe Carrieri; Kenneth Haines; Michael A Gorin; Peter Wiklund; Mani Menon; Ash Tewari
Journal:  Eur Urol Open Sci       Date:  2022-05-20

2.  Bioptic prostatic inflammation correlates with false positive rates of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer.

Authors:  Ugo Giovanni Falagario; Marco Recchia; Giovanni Silecchia; Paola Milillo; Alessia Francavilla; Salvatore Mariano Bruno; Oscar Selvaggio; Gian Maria Busetto; Francesca Sanguedolce; Luca Macarini; Giuseppe Carrieri; Luigi Cormio
Journal:  Cent European J Urol       Date:  2021-07-07

3.  Analysis of the usefulness of magnetic resonance imaging and clinical parameters in the detection of prostate cancer in the first systematic biopsy combined with targeted cognitive biopsy.

Authors:  Natalia Majchrzak; Piotr Cieśliński; Tomasz Milecki; Krzysztof Twardosz; Maciej Głyda; Katarzyna Karmelita-Katulska
Journal:  Cent European J Urol       Date:  2021-07-07

4.  Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data.

Authors:  Tao Tao; Changming Wang; Weiyong Liu; Lei Yuan; Qingyu Ge; Lang Zhang; Biming He; Lei Wang; Ling Wang; Caiping Xiang; Haifeng Wang; Shuqiu Chen; Jun Xiao
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.